

HER2+ Gastric Cancer Market - A Global and Regional Analysis: Focus on Regional Analysis - Analysis and Forecast, 2025-2035

<https://marketpublishers.com/r/H00324CA9A69EN.html>

Date: June 2025

Pages: 0

Price: US\$ 4,900.00 (Single User License)

ID: H00324CA9A69EN

Abstracts

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at order@marketpublishers.com with your request.

This report will be delivered in 7-10 working days.

HER2+ gastric cancer refers to a subtype of gastric (stomach) cancer in which the cancer cells overexpress the HER2 (human epidermal growth factor receptor 2) protein. This protein is involved in the growth and survival of cancer cells. In HER2-positive gastric cancer, the overexpression of HER2 leads to aggressive tumor growth and metastasis.

One of the significant drivers of the global HER2+ gastric cancer market is the rising incidence of gastric cancer. In HER2-positive gastric cancer, the overexpression of HER2 leads to aggressive tumor growth and metastasis. HER2+ gastric cancer tends to grow more rapidly and has a higher likelihood of spreading (metastasizing) to other parts of the body.

Despite the positive growth trajectory, several challenges continue to impact the global HER2+ gastric cancer market. One of the primary challenges is limited screening and early detection methods. The lack of early detection hampers the ability to catch the cancer at an earlier, more treatable stage. This increases the overall mortality rate for gastric cancer and limits the effectiveness of treatments aimed at early-stage tumors.

The global HER2+ gastric cancer market is also facing high cost of treatment. However, High treatment costs limit patient access to the best possible care, leading to disparities

in survival rates. In many countries, patients may not have access to the latest HER2-targeted therapies due to financial constraints, which directly affects their prognosis.

Leading players in the global HER2+ gastric cancer market, such as AstraZeneca, Merck, & Roche are continuously innovating to improve the effectiveness the therapies and products. These companies play pivotal roles in advancing the treatment landscape for HER2-positive gastric cancer through the development of targeted therapies, biosimilars, and innovative drug conjugates. Their ongoing research and collaborations are essential in improving patient outcomes and expanding therapeutic options in this market.

The competitive landscape of the global HER2+ gastric cancer market is diverse, with numerous players across different regions offering a wide range of products. Regional players and local manufacturers are expected to play an important role in the market's growth, especially as demand increases in emerging markets such as Asia-Pacific and Latin America. As consumer preferences shift towards more discreet, comfortable, and affordable therapies, the HER2-positive gastric cancer market will continue to evolve, fostering new opportunities for both established and emerging companies.

Based on region, global HER2+ gastric cancer market segmented into North America, Europe, Asia Pacific and Rest-of-the-World. In 2024, North America accounted for the largest share of HER2+ gastric cancer market. The major market can be attributed to the increasing incidence of gastric cancer and growing healthcare investments and research which are expected to contribute to the significant share of region segment.

As the HER2+ gastric cancer market evolves, emerging trends such as targeted therapies and immunotherapies. The integration of immunotherapeutic agents is gaining momentum, offering new avenues for treatment, especially for patients unresponsive to traditional therapies.

In conclusion, the global HER2+ gastric cancer market is on track for continued growth, driven by the growing healthcare investments and research. The ongoing advancements in product technology and the expansion of care options will continue to shape the market's future. As demand for HER2+ gastric cancer market rises the therapies, both global and regional players will play a key role in meeting the needs of individuals and healthcare systems.

Contents

Executive Summary
Scope and Definition
Market/Product Definition
Key Questions Answered
Analysis and Forecast Note

1. INDUSTRY OUTLOOK

- 1.1 Industry Outlook
 - 1.1.1 Regulatory Landscape
 - 1.1.2 HER2+ Gastric Cancer Market, Patent Landscape
 - 1.1.3 HER2+ Gastric Cancer Market, Clinical Trials Landscape
 - 1.1.4 Key Trends
- 1.2 Market Dynamics
 - 1.2.1 Overview
 - 1.2.1.1 Impact Analysis
 - 1.2.2 Market Drivers
 - 1.2.3 Market Restraints
 - 1.2.4 Market Opportunities

2. GLOBAL HER2+ GASTRIC CANCER MARKET MARKET, BY REGION, \$MILLION, 2023-2035

- 2.1 North America
 - 2.1.1 Key Findings in North America
 - 2.1.2 Business Drivers
 - 2.1.3 Business Challenges
 - 2.1.4 Market Sizing and Forecast
 - 2.1.4.1 North America HER2+ Gastric Cancer Market, By Country
 - 2.1.4.1.1 U.S.
 - 2.1.4.1.2 Canada
- 2.2 Europe
 - 2.2.1 Key Findings in Europe
 - 2.2.2 Business Drivers
 - 2.2.3 Business Challenges
 - 2.2.4 Market Sizing and Forecast
 - 2.2.4.1 Europe HER2+ Gastric Cancer Market, By Country

2.2.4.1.1 Germany

2.2.4.1.2 U.K.

2.2.4.1.3 France

2.2.4.1.4 Italy

2.2.4.1.5 Spain

2.2.4.1.6 Rest-of -Europe

2.3 Asia-Pacific

2.3.1 Key Findings in Asia-Pacific

2.3.2 Business Drivers

2.3.3 Business Challenges

2.3.4 Market Sizing and Forecast

2.3.4.1 Asia-Pacific HER2+ Gastric Cancer Market, By Country

2.3.4.1.1 Japan

2.3.4.1.2 China

2.3.4.1.3 India

2.3.4.1.4 Rest-of-Asia-Pacific

2.4 Rest-of-the-World

2.4.1 Key Findings in Rest-of-the-World

2.4.2 Business Drivers

2.4.3 Business Challenges

2.4.4 Market Sizing and Forecast

3. COMPETITIVE LANDSCAPE AND COMPANY PROFILES

3.1 Competitive Landscape

3.1.1 New Offerings

3.1.2 Mergers and Acquisitions

3.1.3 Partnerships, Alliances, and Business Expansion

3.1.4 Funding Activities

3.1.5 Regulatory Approvals

3.2 AstraZeneca PLC

3.2.1 Overview

3.2.2 Product Portfolio

3.2.3 Target Customers

3.2.4 Key Professionals

3.2.5 Analyst View

3.3 Bristol-Myers Squibb

3.3.1 Overview

3.3.2 Product Portfolio

- 3.3.3 Target Customers
- 3.3.4 Key Professionals
- 3.3.5 Analyst View
- 3.4 Sanofi S A
 - 3.4.1 Overview
 - 3.4.2 Product Portfolio
 - 3.4.3 Target Customers
 - 3.4.4 Key Professionals
 - 3.4.5 Analyst View
- 3.5 Ono Pharmaceutical Co. Ltd
 - 3.5.1 Overview
 - 3.5.2 Product Portfolio
 - 3.5.3 Target Customers
 - 3.5.4 Key Professionals
 - 3.5.5 Analyst View
- 3.6 LintonPharm Ltd
 - 3.6.1 Overview
 - 3.6.2 Product Portfolio
 - 3.6.3 Target Customers
 - 3.6.4 Key Professionals
 - 3.6.5 Analyst View
- 3.7 Pfizer
 - 3.7.1 Overview
 - 3.7.2 Product Portfolio
 - 3.7.3 Target Customers
 - 3.7.4 Key Professionals
 - 3.7.5 Analyst View
- 3.8 Hutchison Medipharma
 - 3.8.1 Overview
 - 3.8.2 Product Portfolio
 - 3.8.3 Target Customers
 - 3.8.4 Key Professionals
 - 3.8.5 Analyst View
- 3.9 Novartis Ag
 - 3.9.1 Overview
 - 3.9.2 Product Portfolio
 - 3.9.3 Target Customers
 - 3.9.4 Key Professionals
 - 3.9.5 Analyst View

3.10 Shanghai Henlius Biotech Inc.

3.10.1 Overview

3.10.2 Product Portfolio

3.10.3 Target Customers

3.10.4 Key Professionals

3.10.5 Analyst View

4. RESEARCH METHODOLOGY

List Of Figures

LIST OF FIGURES

Figure: Global HER2+ Gastric Cancer Market, Dynamics Impact Analysis

Figure: Global HER2+ Gastric Cancer Market (by Region), \$Million, 2024 and 2035

Figure: Global HER2+ Gastric Cancer Market Coverage

Figure: Global HER2+ Gastric Cancer Market Key Trends, Analysis

List Of Tables

LIST OF TABLES

Table: Global HER2+ Gastric Cancer Market, Patent Analysis, January 2022-March 2025

Table: Global HER2+ Gastric Cancer Market Dynamics, Impact Analysis

COMPANIES MENTIONED

AstraZeneca PLC
Bristol-Myers Squibb
Sanofi S A
Ono Pharmaceutical Co. Ltd
LintonPharm Ltd
Pfizer
Hutchison Medipharma
Novartis Ag
Shanghai Henlius Biotech Inc.

I would like to order

Product name: HER2+ Gastric Cancer Market - A Global and Regional Analysis: Focus on Regional Analysis - Analysis and Forecast, 2025-2035

Product link: <https://marketpublishers.com/r/H00324CA9A69EN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H00324CA9A69EN.html>